title: Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
abstract: OBJECTIVE
  To determine variables associated with glycemic and body weight responses when adding exenatide to basal insulin-treated type 2 diabetes.
  
  
  METHODS
  Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
  
  
  RESULTS
  Exenatide participants had greater A1C reductions compared with optimized insulin glargine alone, irrespective of baseline A1C (P < 0.001). Exenatide participants with longer diabetes duration and those with lower BMI had greater A1C reductions (P < 0.01). Exenatide participants lost more weight, regardless of baseline A1C or BMI (P < 0.05). Exenatide participants with longer diabetes duration lost the most weight (P < 0.001).
  
  
  CONCLUSIONS
  Exenatide added to optimized basal insulin was associated with improved glycemic control and weight loss, irrespective of baseline A1C, diabetes duration, and BMI. Changes were evident in modestly obese patients and in those with longer diabetes duration.
authors.affiliation: Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas; 2Eli Lilly and Company,Indianapolis, Indiana, USA.
authors.forename: Julio
authors.initials: J
authors.lastname: Rosenstock
authors.forename: Sylvia K
authors.initials: SK
authors.lastname: Shenouda
authors.forename: Richard M
authors.initials: RM
authors.lastname: Bergenstal
authors.forename: John B
authors.initials: JB
authors.lastname: Buse
authors.forename: Leonard C
authors.initials: LC
authors.lastname: Glass
authors.forename: Cory R
authors.initials: CR
authors.lastname: Heilmann
authors.forename: Anita Y M
authors.initials: AY
authors.lastname: Kwan
authors.forename: Leigh A
authors.initials: LA
authors.lastname: MacConell
authors.forename: Byron James
authors.initials: BJ
authors.lastname: Hoogwerf
mesh_terms: D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010455:Peptides; D014688:Venoms; D000069036:Insulin Glargine; D000077270:Exenatide